FDA approves Hybridyne's gamma camera for endocavity imaging
Hybridyne Imaging Technologies in Toronto has received FDA 510(k) clearance to market ProxiScan, a gamma camera for the detection of cancer and other abnormalities in the body.
ProxiScan can be used in imaging the distribution of radionuclides in the human body using planar imaging techniques. The system may also be used intra-operatively, on pathological specimens and for endocavity applications if a protective sheath is used, said the company.
The unique component of the technology is a small cadmium zinc telluride-based compact gamma camera developed by Hybridyne in collaboration with scientists at Brookhaven National Laboratory in Upton, N.Y.
ProxiScan can be used for imaging prostate, cervical, uterine, colorectal and breast cancers. It can also be optimized for surgical use as a probe to guide the removal of cancerous tumors while minimizing damage to surrounding healthy tissues, added Hybridyne.
ProxiScan can be used in imaging the distribution of radionuclides in the human body using planar imaging techniques. The system may also be used intra-operatively, on pathological specimens and for endocavity applications if a protective sheath is used, said the company.
The unique component of the technology is a small cadmium zinc telluride-based compact gamma camera developed by Hybridyne in collaboration with scientists at Brookhaven National Laboratory in Upton, N.Y.
ProxiScan can be used for imaging prostate, cervical, uterine, colorectal and breast cancers. It can also be optimized for surgical use as a probe to guide the removal of cancerous tumors while minimizing damage to surrounding healthy tissues, added Hybridyne.